Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.70.

YMAB has been the topic of a number of analyst reports. HC Wainwright decreased their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Morgan Stanley decreased their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. Oppenheimer decreased their price target on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday. Truist Financial decreased their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, Wedbush reaffirmed an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd.

Y-mAbs Therapeutics Stock Down 12.5%

NASDAQ YMAB opened at $3.64 on Thursday. The company's 50 day moving average is $4.50 and its 200-day moving average is $7.26. Y-mAbs Therapeutics has a 12-month low of $3.63 and a 12-month high of $16.11. The firm has a market cap of $164.81 million, a P/E ratio of -6.74 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. Equities analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 22.50% of the company's stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Brooklyn Investment Group increased its stake in shares of Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after acquiring an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Y-mAbs Therapeutics during the 4th quarter valued at about $46,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $49,000. Corton Capital Inc. bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $55,000. Finally, EntryPoint Capital LLC bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $56,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.